Annotation Detail
Information
- Associated Genes
- ALK
- Associated Variants
- ALK EML4-ALK V1180L
- Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- The alectinib resistant cell line H3122 CHR-A1 was generated by culturing of the EML4-ALK (variant 1) containing cell line H3122 with increasing levels of alectinib. Molecular characterization of H3122 CHR-A1 revealed a V1180L ALK kinase domain mutation. The H3122 CHR-A1 cell line required approximately 10 fold increase in crizotinib concentration to induce similar levels of cell death to H3122. Ectopic expression of EML4-ALK V1180L rendered Ba/F3 cells moderately less susceptible to crizotinib than ectopic EML4-ALK.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1288
- Gene URL
- https://civic.genome.wustl.edu/links/genes/1
- Variant URL
- https://civic.genome.wustl.edu/links/variants/528
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Crizotinib
- Evidence Level
- D
- Clinical Significance
- Resistance
- Pubmed
- 25228534
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Crizotinib | Resitance or Non-Reponse | true |